Search
Search Results
-
Passive immunotherapy for Alzheimer’s disease: challenges & future directions
Passive immunotherapy with specific antibodies targeting Amyloid β (Aβ) peptide or tubulin-associated unit (tau) protein has emerged as a promising...
-
Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia
Neurodegenerative dementia can result from multiple underlying abnormalities, including neurotransmitter imbalances, protein aggregation, and other...
-
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early...
-
-
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
The amyloid cascade hypothesis is a useful framework for therapeutic development in Alzheimer’s disease (AD). Amyloid b 1-42 (Aβ) has been the main...
-
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves...
-
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
BackgroundClinical trials in Alzheimer’s disease (AD) had high failure rates for several reasons, including the lack of biological endpoints....
-
Pathophysiology and Management Approaches in Alzheimer’s Disease
Alzheimer’s disease is recognized as a progressive multifarious neurodegenerative disorder that is pathologically characterized by the deposition of...
-
Emerging diagnostics and therapeutics for Alzheimer disease
Alzheimer disease (AD) is the most common contributor to dementia in the world, but strategies that slow or prevent its clinical progression have...
-
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate clinical efficacy. However, four anti-Aβ antibodies have...
-
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected individuals, their families and caregivers, and healthcare...
-
PET Imaging of Amyloid and Tau in Alzheimer’s Disease
Alzheimer’s disease (AD)Alzheimer’s disease (AD) is characterized by the extracellular deposition of amyloid-β (Aβ)Amyloid-β (Aβ) plaques,...
-
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Alzheimer’s disease (AD) is the most common neurodegenerative disease in the elderly worldwide. However, the complexity of AD pathogenesis leads to...
-
Recent advances in Alzheimer’s disease pathogenesis and therapeutics from an immune perspective
BackgroundThe prevalence of Alzheimer’s disease, the most common type of dementia, is continuously increasing. Many recent reports have indicated...
-
Is the Persistence of the Amyloid Cascade Hypothesis a Result of Constant Confirmation Bias?
Whenever a hypothesis has been around for a very long time, chances are that it has a constantly growing number of followers and a diminishing number...
-
Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease
The use of biomarker-led clinical trial designs has been transformative for investigating amyloid-targeting therapies for Alzheimer’s disease (AD)....
